Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

53.70 

-0.29 -0.5%

as of Nov 26 '14 16:00

52 Week Range:

41.99 80.42


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. Its late-stage development programs include Promacta, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Captisol-enabled Melphalan IV for the multiple myeloma transplant setting; Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis; and Nexterone, an injectable formulation. The company’s late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program for the treatment of Alzheimer’s disease; Captisol-enabled Carbamazepine-IV for the management of acute seizure disorder for hospital or emergency settings; and Captisol-enabled Delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections. It also offers Sparsentan that is in Phase II clinical trials for kidney diseases; Lasofoxifene, an estrogen partial agonist for osteoporosis treatment and other diseases; and Captisol-enabled Topiramate Injection, which is in Phase I clinical trials for the treatment of partial onset or primary generalized tonic-clonic seizures. In addition, the company’s preclinical stage products include HepDirect for liver diseases; Oral Human Granulocyte Colony Stimulating Factor for the treatment of Neutropenia; and IRAK4 Inhibitor for inflammation. Further, it provides Glucagon Receptor Antagonist that is in Phase I clinical trials for diabetes; Selective Androgen Receptor Modulator, which is in Phase II clinical trials for the therapeutic benefits; and Captisol-Enabled Clopidogrel that is in Phase III clinical trials for anti-coagulants. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

Item Name Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Equity (BVPS) -1.88
-6.11
-8.94
2.07
1.83
-0.66
0.19
-0.25
0.42
1.31
2.42
growth rate 0.0% 0.0% 100.0% -11.6% -100.0% 100.0% -100.0% 100.0% 211.9% 84.7%
Earnings BIT -94.41
-44.91
36.34
-174.27
-53.46
-97.52
-9.87
-15.40
-2.95
-3.87
9.21
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -7.90
-46.30
-17.00
-15.70
-20.90
-3.20
-34.50
-15.00
22.99
-118.50
121.95
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0%
ROA -13.10
-14.25
-11.25
-9.91
112.83
-56.92
-1.24
-9.54
10.28
-0.47
10.93
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0%
ROE -51.80
36.10
36.70
-142.60
997.71
-1,046.50
-69.00
-365.80
536.00
-3.00
30.01
growth rate 100.0% 1.7% -100.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0%
ROIC 572.76
-786.06
35.28
3.76
20.13
growth rate -100.0% 100.0% -89.3% 435.4%
Cur. Ratio 0.80
0.57
1.38
2.16
1.33
1.31
1.11
0.74
0.67
0.86
growth rate -28.8% 142.1% 56.5% -38.4% -1.5% -15.3% -33.3% -9.5% 28.4%
Quick Ratio 0.66
0.46
1.07
1.85
1.31
1.22
1.08
0.67
0.60
0.78
growth rate -30.3% 132.6% 72.9% -29.2% -6.9% -11.5% -38.0% -10.5% 30.0%
Leverage 11.92
5.95
37.88
14.15
3.94
2.11
growth rate -50.1% 152.3% -38.9% -72.2% -46.5%
Balance Sheet Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Acct.Receivable 0.00
0.60
1.00
12.54
8.92
6.55
growth rate 66.7% 1,154.4% -28.9% -26.5%
Acct.Payable 16.12
12.40
10.86
growth rate -23.1% -12.4%
Cur.Assets 93.90
68.20
37.00
32.23
23.82
24.88
growth rate -27.4% -45.8% -12.9% -26.1% 4.4%
Total Assets 171.40
141.80
75.60
120.58
104.26
104.71
growth rate -17.3% -46.7% 59.5% -13.5% 0.4%
Cash 28.80
16.00
3.30
7.04
12.38
11.64
growth rate -44.4% -79.4% 113.4% 75.8% -6.0%
Inventory 0.00
0.00
0.00
1.30
1.70
1.39
growth rate 30.4% -18.0%
Cur.Liabilities 70.60
52.20
33.50
43.64
35.44
28.94
growth rate -26.1% -35.8% 30.3% -18.8% -18.3%
Liabilities 181.80
138.10
80.40
104.05
77.78
55.10
growth rate -24.0% -41.8% 29.4% -25.3% -29.2%
LT Debt 170.05
171.09
170.18
2.16
0.63
49.70
36.30
0.00
28.65
19.41
3.07
growth rate 0.6% -0.5% -98.7% -71.0% 7,826.6% -27.0% -100.0% -32.3% -84.2%
Equity -98.07
39.70
41.46
1.98
3.70
3.50
8.19
26.49
49.61
growth rate 100.0% 4.4% -95.2% 86.9% -5.4% 133.9% 223.6% 87.3%
Common Shares 12.00
12.00
13.00
16.00
16.00
19.00
20.00
20.00
20.00
21.00
growth rate 0.0% 8.3% 23.1% 0.0% 18.8% 5.3% 0.0% 0.0% 5.0%
Cash Flow Statement Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Capital Expenditures 6.92
3.60
35.60
1.78
0.44
0.40
0.40
0.70
0.08
0.60
0.38
growth rate -48.0% 888.9% -95.0% -75.3% -9.1% 0.0% 75.0% -88.9% 662.8% -36.6%
Cash Dividends 0.00
0.00
0.00
0.00
252.74
0.00
0.00
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 0.31
5.75
8.37
-138.52
-97.73
-20.63
-33.80
-27.07
-1.17
0.16
20.69
growth rate 1,754.8% 45.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 12,750.9%
FCF per Share 0.18
-2.21
-10.44
-6.00
-1.33
-1.82
-1.38
-0.06
-0.02
0.81
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Sale Purchase of Stock 0.00
6.42
3.13
growth rate 100.0% -51.3%
FCF -6.61
2.00
-27.00
-140.00
-98.00
-21.00
-34.00
-27.00
-1.00
-0.40
17.00
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Income Statement Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Sales 81.12
112.11
10.22
3.98
12.89
27.30
38.90
23.50
30.04
31.39
48.97
growth rate 38.2% -90.9% -61.1% 223.9% 111.8% 42.5% -39.6% 27.8% 4.5% 56.0%
Op.Income -97.30
-10.00
-29.30
9.71
-2.67
8.83
growth rate 0.0% 0.0% 100.0% -100.0% 100.0%
IBT -97.50
-9.90
-15.40
-3.56
-3.87
9.21
growth rate 0.0% 0.0% 0.0% 0.0% 100.0%
Net Income -98.10
-1.90
-10.40
9.71
-2.67
8.83
growth rate 0.0% 0.0% 100.0% -100.0% 100.0%
EPS -8.02
-3.66
-2.94
-2.34
17.22
-6.18
-0.12
-0.53
0.52
-0.03
0.55
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0%
Gross Profit 93.85
10.22
3.98
12.89
27.30
38.90
23.50
25.13
27.79
43.24
growth rate -89.1% -61.1% 223.9% 111.8% 42.5% -39.6% 6.9% 10.6% 55.6%
R&D 30.80
39.90
22.10
10.29
10.79
9.27
growth rate 29.6% -44.6% -53.4% 4.9% -14.1%

Quarterly Statements

Item Name Jun '13 Sep '13 Dec '13 Mar '14 Jun '14
Balance Sheet
Acct.Receivable 0.70
10.01
6.55
5.36
3.52
growth rate 1,330.6% -34.6% -18.2% -34.3%
Acct.Payable 10.50
10.86
10.70
9.87
growth rate 3.4% -1.5% -7.7%
Cur.Assets 14.60
16.64
24.88
33.40
28.59
growth rate 13.9% 49.6% 34.3% -14.4%
Total Assets 99.60
101.68
104.71
105.47
99.85
growth rate 2.1% 3.0% 0.7% -5.3%
Cash 5.90
3.27
11.64
12.98
14.54
growth rate -44.6% 255.8% 11.5% 12.0%
Inventory 2.30
1.84
1.39
1.95
0.82
growth rate -20.1% -24.3% 40.0% -58.1%
Cur.Liabilities 32.60
32.46
28.94
21.01
18.62
growth rate -0.4% -10.9% -27.4% -11.4%
Liabilities 60.30
56.86
55.10
40.47
35.68
growth rate -5.7% -3.1% -26.6% -11.8%
LT Debt 6.30
3.73
3.07
2.34
1.59
growth rate -40.9% -17.6% -23.8% -32.2%
Equity 39.30
44.82
49.61
65.00
64.17
growth rate 14.0% 10.7% 31.0% -1.3%
Common Shares 21.44
21.53
20.47
20.72
20.78
growth rate 0.4% -4.9% 1.2% 0.3%
Cash Flow Statement Jun '13 Sep '13 Dec '13 Mar '14 Jun '14
Capital Expenditures 0.10
0.26
0.11
0.01
-0.01
growth rate 163.0% -56.7% -94.7% -100.0%
Cash Dividends
growth rate
Cash From OA 6.90
8.70
12.03
2.58
4.01
growth rate 26.1% 38.3% -78.6% 55.5%
Sale Purchase of Stock 1.24
0.70
3.20
0.45
growth rate -43.8% 357.1% -85.8%
FCF 3.20
-0.50
11.90
2.60
4.00
growth rate -100.0% 100.0% -78.2% 53.9%
Income Statement Jun '13 Sep '13 Dec '13 Mar '14 Jun '14
Sales 9.60
13.01
14.74
15.96
10.61
growth rate 35.5% 13.3% 8.3% -33.5%
Op.Income 1.50
1.97
1.87
2.10
1.29
growth rate 31.0% -4.9% 12.2% -38.6%
IBT 3.80
2.03
2.01
2.15
1.24
growth rate -46.7% -1.0% 7.2% -42.3%
Net Income 6.10
1.97
1.87
2.10
1.29
growth rate -67.8% -4.9% 12.2% -38.6%
EPS 0.30
0.09
0.09
0.10
0.07
growth rate -70.0% 0.0% 11.1% -30.0%
Gross Profit 8.40
10.47
13.42
13.51
9.42
growth rate 24.6% 28.2% 0.7% -30.2%
R&D 2.00
2.41
2.37
3.13
2.69
growth rate 20.7% -1.6% 31.9% -14.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.92)

YOY Growth Grade:

D (36.68)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 160.76 162.73 22.67
EPS / Growth 25.6% 0.33 30.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 25.6% 35.2% 46.2%
Future PE 22.67 84.60 91.93
Future EPS 3.22 6.73 14.70
Value Price
MOS
18.04
-66.4%
140.72
162.1%
334.10
522.2%
MOS Price 9.02 70.36 167.05
IRT 15.47 12.46 10.38

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.